Boehringer Ingelheim and Click Therapeutics will together develop and commercialise of a prescription-based digital therapeutic for schizophrenia.
It will utilise cognitive and neurobehavioral mechanisms delivered through Click’s proprietary engagement platform with the goal of reducing cognitive deficits and impaired social functioning in patients with schizophrenia.
Together the two companies will combine their expertise to develop a novel mobile application – CT-155 – which combines multiple clinically validated therapeutic interventions to help schizophrenia patients modify their behaviour to achieve positive clinical outcomes alone and in combination with pharmaceutical therapy options.
The partnership aims to provide better tools and resources to those living with schizophrenia, where there remains a huge unmet need due to lack of access to psychosocial intervention therapies.
“Partnering with Boehringer Ingelheim allows us to leverage their considerable experience in the clinical development and global commercialization of new treatment options for neuropsychiatric diseases to improve the efficacy and reach of our digital therapeutic software,” said David Benshoof Klein, CEO of Click Therapeutics.
Click Therapeutics will be primarily responsible for research and development activities, and will support Boehringer Ingelheim as it undertakes worldwide commercialization activities.
The company will receive an upfront payment and funding for R&D activities as well as clinical, regulatory and commercial milestones representing a total deal value of over $500 million. Additionally, Click Therapeutics will receive tiered royalties on annual net sales of CT-155 worldwide.